Neoantigen DNA Vaccines Safe, Induce Response in Triple-Negative Breast Cancer
By Elana Gotkine HealthDay Reporter
THURSDAY, Nov. 14, 2024 -- Neoantigen DNA vaccines are safe and capable of inducing neoantigen-specific immune responses in patients with triple-negative breast cancer, according to a study published online Nov. 14 in Genome Medicine.
Xiuli Zhang, M.D., from the Washington University School of Medicine in St. Louis, and colleagues developed a neoantigen DNA vaccine platform capable of presenting human leukocyte antigen class I and II epitopes. Tumor/normal exome sequencing and tumor RNA sequencing were used to identify expressed somatic mutations; cancer neoantigens were identified and prioritized using neoantigen prediction algorithms in order to facilitate vaccine design. The neoadjuvant DNA vaccines were administered in the adjuvant setting in a phase 1 clinical trial involving triple-negative breast cancer patients with persistent disease on surgical pathology following neoadjuvant chemotherapy. Vaccines were monitored for safety and immune responses.
Overall, 18 patients received three doses of a neoantigen DNA vaccine encoding 11 neoantigens on average per patient. The researchers found that the vaccines were well tolerated, with few adverse events reported. Fourteen of the patients had neoantigen-specific T-cell responses. In the cohort of vaccinated patients, recurrence-free survival was 87.5 percent at a median follow-up of 36 months.
"These results support further study of the neoantigen DNA vaccine platform in triple-negative breast cancer and other low mutation burden cancers," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
Widespread Decline Seen in MMR Vaccination Rates After COVID-19
THURSDAY, June 5, 2025 -- A widespread decrease in measles-mumps-rubella (MMR) vaccination rates was seen after the COVID-19 pandemic, according to a research letter published...
Odds of Advanced Cancer, Breast Cancer Death Lower in Screen-Detected Disease
THURSDAY, June 5, 2025 -- For patients aged 40 years or older, screen-detected breast cancer is associated with lower odds of advanced cancer, mastectomy, and breast...
Nodal Irradiation Does Not Reduce Recurrence, Death for ypN0 Breast Cancer
THURSDAY, June 5, 2025 -- For patients with node-positive breast cancer who become pathologically tumor-free with negative axillary nodes (ypN0) after neoadjuvant chemotherapy...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.